Cloning of a type 2 diabetes modifier in obese mice

在肥胖小鼠中克隆 2 型糖尿病调节剂

基本信息

  • 批准号:
    7524305
  • 负责人:
  • 金额:
    $ 40.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-30 至 2012-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Over 7% (21M) of the U.S. population has diabetes (over 90% of which is type 2 = T2D). Another 54M have "prediabetes" (all T2D). The human tragedy aside, direct medical costs associated with diabetes in the United States currently exceed $132 billion a year and consume ~10% of health care costs in industrialized nations. Diabetes is the leading cause of both end stage renal disease and blindness (in people aged 20-74 years), and its association with cardiovascular disease increases mortality rates two-fold. The worldwide prevalence of T2D is projected to more than double over the next 20 years. Although intensive genetic analyses of human populations have confirmed contributory roles for some specific genes, these cannot account - even in the aggregate - for powerful genetic predisposition T2D. Obesity is clearly related to the occurrence of diabetes. Physiologically, this is apparently due to the stress that obesity-related insulin resistance places on the insulin- producing cells of the pancreas. But the molecular basis for this striking association is not known. It is possible that part of this differential susceptibility derives from genetically mediated differences in the starting numbers of insulin producing beta cells among individuals. If so, it is very important to identify the relevant genes. Mouse strains differ widely in susceptibility to diabetes when made obese. We exploited this characteristic to map diabetes-susceptibility regions of the mouse genome in genetics crosses between a diabetes-susceptible and a resistant strain. We used molecular genetic methods to find a novel gene, lisch-like (Ll) that appears to account for some aspects of this strain-related difference in mice. The gene affects the early development and replication of beta cells, leaving animals with the susceptible version of the gene with a reduced beta cell mass that then predisposes them to diabetes. The proposed studies are intended to confirm the role of this gene in the etiology of T2D and to reveal how this novel molecule produces these effects. The Hypothesis underlying the proposed studies is that LL regulates generation and survival of islet beta cells. In Aim 1 we will examine the systemic and cellular physiology of mice with induced mutations causing under or over-activity of the Ll gene. These studies are designed to confirm the gene's role in diabetes and to understand the molecular physiology of its activity. In Aim 2 Assays of protein biosynthesis, processing, and sub-cellular localization, signaling properties and structure/function relationships will be employed in gain- and loss-of-function experiments of LL. The human version of the Ll gene is 90% identical to that in the mouse, and is located in a region of the human genome that has been repeatedly linked to T2D in genetic studies. Ll could play a role in that linkage. Elucidation of the mechanisms by which LL loss-of-function produces diabetes-susceptibility may reveal novel pathways critical to cell development and survival in the context of insulin resistance and gluco-/lipotoxicity imposed by obesity. PUBLIC HEALTH RELEVANCE: Nearly twenty one million people in the United States (over 7% of the population), and over 246 million people worldwide are afflicted with type 2 diabetes (T2D); about 54 million Americans have pre-diabetes. If the incidence of T2D continues to increase at the present rate, one in three Americans, and 1 in 2 minorities, born in 2000 will develop diabetes in their lifetime. This project will analyze the molecular function of a newly discovered gene that may account for some aspects of diabetes susceptibility in humans.
描述(由申请人提供):超过7%(2100万)的美国人口患有糖尿病(其中超过90%为2型= T2D)。另有5400万人患有“前驱糖尿病”(均为t2dm)。撇开人类的悲剧不谈,目前美国与糖尿病相关的直接医疗费用每年超过1320亿美元,占工业化国家医疗保健费用的10%左右。糖尿病是导致终末期肾病和失明(20-74岁人群)的主要原因,其与心血管疾病的关联使死亡率增加了两倍。预计在未来20年,t2dm的全球患病率将增加一倍以上。尽管对人类群体的密集遗传分析已经证实了某些特定基因的贡献作用,但这些不能解释——即使是总体上——强大的遗传易感性T2D。肥胖显然与糖尿病的发生有关。从生理学上讲,这显然是由于肥胖相关的胰岛素抵抗对胰腺中产生胰岛素的细胞造成的压力。但这种惊人联系的分子基础尚不清楚。这种不同的易感性可能部分源于基因介导的个体之间产生胰岛素的β细胞起始数量的差异。如果是这样,鉴定相关基因是非常重要的。小鼠品系在肥胖时对糖尿病的易感性差异很大。我们利用这一特点,在糖尿病易感菌株和抗性菌株之间的遗传杂交中绘制了小鼠基因组的糖尿病易感区域。我们使用分子遗传学方法找到了一种新的基因,lisch-like (Ll),它似乎解释了小鼠中这种品系相关差异的某些方面。该基因影响β细胞的早期发育和复制,使携带该基因易感版本的动物的β细胞数量减少,从而使它们易患糖尿病。提出的研究旨在确认该基因在T2D病因学中的作用,并揭示这种新分子如何产生这些作用。所提出的研究的假设是LL调节胰岛β细胞的产生和存活。在目标1中,我们将检查引起Ll基因活性不足或过度的诱导突变小鼠的系统和细胞生理学。这些研究旨在确认该基因在糖尿病中的作用,并了解其活动的分子生理学。在Aim 2中,蛋白质的生物合成、加工和亚细胞定位、信号特性和结构/功能关系将用于LL的功能增益和功能丧失实验。人类的Ll基因与小鼠的90%相同,并且位于人类基因组的一个区域,该区域在遗传研究中多次与T2D相关。我可以在这种联系中发挥作用。通过阐明LL功能丧失产生糖尿病易感性的机制,可能揭示在胰岛素抵抗和肥胖造成的糖/脂毒性的背景下,对细胞发育和存活至关重要的新途径。公共卫生相关性:美国有近2100万人(占人口的7%以上),全球有超过2.46亿人患有2型糖尿病(T2D);大约有5400万美国人患有糖尿病前期。如果T2D的发病率继续以目前的速度增长,2000年出生的三分之一的美国人和两分之一的少数民族将在其一生中患上糖尿病。该项目将分析一个新发现的基因的分子功能,该基因可能解释人类糖尿病易感性的某些方面。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RUDOLPH L LEIBEL其他文献

RUDOLPH L LEIBEL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RUDOLPH L LEIBEL', 18)}}的其他基金

Neuroanatomic and Functional Characterization of Cerebellar Circuits Mediating Ingestive Behaviors
介导摄取行为的小脑回路的神经解剖学和功能特征
  • 批准号:
    10667656
  • 财政年份:
    2022
  • 资助金额:
    $ 40.08万
  • 项目类别:
Neuroanatomic and Functional Characterization of Cerebellar Circuits Mediating Ingestive Behaviors
介导摄取行为的小脑回路的神经解剖学和功能特征
  • 批准号:
    10522478
  • 财政年份:
    2022
  • 资助金额:
    $ 40.08万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    9259935
  • 财政年份:
    2017
  • 资助金额:
    $ 40.08万
  • 项目类别:
Molecular Biology/Molecular Genetics Core
分子生物学/分子遗传学核心
  • 批准号:
    8135912
  • 财政年份:
    2011
  • 资助金额:
    $ 40.08万
  • 项目类别:
Molecular Genetics Core
分子遗传学核心
  • 批准号:
    7418668
  • 财政年份:
    2007
  • 资助金额:
    $ 40.08万
  • 项目类别:
Molecular Biology/Molecular Genetics Core
分子生物学/分子遗传学核心
  • 批准号:
    7120332
  • 财政年份:
    2006
  • 资助金额:
    $ 40.08万
  • 项目类别:
ENERGY HOMEOSTASIS IN HUMAN OBESITY
人类肥胖中的能量稳态
  • 批准号:
    7205888
  • 财政年份:
    2005
  • 资助金额:
    $ 40.08万
  • 项目类别:
Conference on Obesity
肥胖会议
  • 批准号:
    6887148
  • 财政年份:
    2004
  • 资助金额:
    $ 40.08万
  • 项目类别:
Leptin in Human Energy and Neuroendocrine Homeostasis
瘦素在人体能量和神经内分泌稳态中的作用
  • 批准号:
    6671285
  • 财政年份:
    2003
  • 资助金额:
    $ 40.08万
  • 项目类别:
Energy Homeostasis in Human Obesity
人类肥胖中的能量稳态
  • 批准号:
    7044999
  • 财政年份:
    2003
  • 资助金额:
    $ 40.08万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 40.08万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了